Biogen's Amevive (alefacept) is available Feb. 3 following approval Jan. 30 for "treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy." Biogen's sales force of 95 is focusing on the top 3,000 dermatologist prescribers of systemic psoriasis therapies; the firm will highlight Amevive's tolerability profile and improved duration of action. Labeling, which includes a bolded warning on the need for weekly blood monitoring, recommends that each 12-week course of Amevive be followed by a minimum of 12 weeks off therapy. Amevive is priced at $560 per once-weekly 7.5 mg IV bolus and $796 per 15 mg weekly intramuscular injection, for cost of $6,720 to $9,552 per 12-week course, or about $13,400 to $17,100 per year. Monitoring, at Biogen's estimate of $55 per week, would add another $1,430 per yea
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
